Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

111 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
MRI as an outcome in multiple sclerosis clinical trials.
Daumer M, Neuhaus A, Morrissey S, Hintzen R, Ebers GC. Daumer M, et al. Neurology. 2009 Feb 24;72(8):705-11. doi: 10.1212/01.wnl.0000336916.38629.43. Epub 2008 Dec 10. Neurology. 2009. PMID: 19073945
METHODS: In a clinical trial database comprised of 31 relapsing-remitting and secondary progressive MS trial placebo groups, we assessed relationships between 1) T2 lesion load (TLL) change and disability change and 2) gadolinium enhancement of MS lesions and on-study rela …
METHODS: In a clinical trial database comprised of 31 relapsing-remitting and secondary progressive MS trial placebo groups, we asses …
Placebo cohorts in phase-3 MS treatment trials - predictors for on-trial disease activity 1990-2010 based on a meta-analysis and individual case data.
Stellmann JP, Neuhaus A, Herich L, Schippling S, Roeckel M, Daumer M, Martin R, Heesen C. Stellmann JP, et al. PLoS One. 2012;7(11):e50347. doi: 10.1371/journal.pone.0050347. Epub 2012 Nov 29. PLoS One. 2012. PMID: 23209717 Free PMC article.
We consider a better understanding of this phenomenon essential for valuing the effects of new drugs and by designing new trials. ...RESULTS: Data from 12 published and one unpublished trial show a decrease of ARR from 1988 to 2012 (adjR(2) = 0.807, p<0.0001). .. …
We consider a better understanding of this phenomenon essential for valuing the effects of new drugs and by designing new trials. ... …
Prognostic risk estimates of patients with multiple sclerosis and their physicians: comparison to an online analytical risk counseling tool.
Heesen C, Gaissmaier W, Nguyen F, Stellmann JP, Kasper J, Köpke S, Lederer C, Neuhaus A, Daumer M. Heesen C, et al. PLoS One. 2013 May 17;8(5):e59042. doi: 10.1371/journal.pone.0059042. Print 2013. PLoS One. 2013. PMID: 23690916 Free PMC article.
Simultaneously, patients and physicians are increasingly confronted with making treatment decisions at an early stage, which requires taking individual prognoses into account to strike a good balance between benefits and harms of treatments. ...
Simultaneously, patients and physicians are increasingly confronted with making treatment decisions at an early stage, which requires taking …
Validating predictors of disease progression in a large cohort of primary-progressive multiple sclerosis based on a systematic literature review.
Stellmann JP, Neuhaus A, Lederer C, Daumer M, Heesen C. Stellmann JP, et al. PLoS One. 2014 Mar 20;9(3):e92761. doi: 10.1371/journal.pone.0092761. eCollection 2014. PLoS One. 2014. PMID: 24651401 Free PMC article. Review.
OBJECTIVE: To analyse the impact of published predictors on EDSS disease progression in a large cohort of PPMS patients. METHODS: A systematic literature research was performed to identify predictors for disease progression in PPMS. ...Our pooled cohort of 597 PPMS …
OBJECTIVE: To analyse the impact of published predictors on EDSS disease progression in a large cohort of PPMS patients. METHODS: …
Onset of secondary progressive phase and long-term evolution of multiple sclerosis.
Scalfari A, Neuhaus A, Daumer M, Muraro PA, Ebers GC. Scalfari A, et al. J Neurol Neurosurg Psychiatry. 2014 Jan;85(1):67-75. doi: 10.1136/jnnp-2012-304333. Epub 2013 Mar 13. J Neurol Neurosurg Psychiatry. 2014. PMID: 23486991
Baseline clinical features of early relapse frequency and age at onset can be used to select groups at higher risk of developing severe disability based on the probability of their disease becoming progressive within a defined time period....
Baseline clinical features of early relapse frequency and age at onset can be used to select groups at higher risk of developing severe disa …
The natural history of multiple sclerosis: a geographically based study 10: relapses and long-term disability.
Scalfari A, Neuhaus A, Degenhardt A, Rice GP, Muraro PA, Daumer M, Ebers GC. Scalfari A, et al. Brain. 2010 Jul;133(Pt 7):1914-29. doi: 10.1093/brain/awq118. Epub 2010 Jun 9. Brain. 2010. PMID: 20534650 Free PMC article.
Relapse reduction is a common therapeutic target but clinical trials have shown dissociation between relapse suppression and disability accumulation. ...They increase the probability of its occurrence, its latency and influence--to a lesser degree--its slope. The pr …
Relapse reduction is a common therapeutic target but clinical trials have shown dissociation between relapse suppression and disabili …
Early relapses, onset of progression, and late outcome in multiple sclerosis.
Scalfari A, Neuhaus A, Daumer M, Deluca GC, Muraro PA, Ebers GC. Scalfari A, et al. JAMA Neurol. 2013 Feb;70(2):214-22. doi: 10.1001/jamaneurol.2013.599. JAMA Neurol. 2013. PMID: 23407713
CONCLUSIONS: Our results indicate dissociation between early inflammatory attacks and onset of the SP phase and further question the validity of relapse frequency as a surrogate marker for late disability. Among the group with frequent early relapses, we observed a
CONCLUSIONS: Our results indicate dissociation between early inflammatory attacks and onset of the SP phase and further question the validit …
Fampridine and real-life walking in multiple sclerosis: Low predictive value of clinical test for habitual short-term changes.
Stellmann JP, Jlussi M, Neuhaus A, Lederer C, Daumer M, Heesen C. Stellmann JP, et al. J Neurol Sci. 2016 Sep 15;368:318-25. doi: 10.1016/j.jns.2016.07.051. Epub 2016 Jul 25. J Neurol Sci. 2016. PMID: 27538657
OBJECTIVE: To investigate the association between clinical response criteria and habitual mobility in MS patients starting a fampridine treatment. ...Accelerometry opens a new perspective on mobility measurment, but the current data do not show a consistent e …
OBJECTIVE: To investigate the association between clinical response criteria and habitual mobility in MS patients starting a fampridi …
Prognosis of the individual course of disease: the elements of time, heterogeneity and precision.
Daumer M, Neuhaus A, Herbert J, Ebers G. Daumer M, et al. J Neurol Sci. 2009 Dec;287 Suppl 1:S50-5. doi: 10.1016/S0022-510X(09)71301-2. J Neurol Sci. 2009. PMID: 20106349
An alternative to the EDSS is the Multiple Sclerosis Severity Score (MSSS), a severity scale which relates clinical disability to disease duration. The MSSS was originally developed from a database of nearly ten thousand patients from eleven European countries and A …
An alternative to the EDSS is the Multiple Sclerosis Severity Score (MSSS), a severity scale which relates clinical disability to dis …
Association between walking speed and age in healthy, free-living individuals using mobile accelerometry--a cross-sectional study.
Schimpl M, Moore C, Lederer C, Neuhaus A, Sambrook J, Danesh J, Ouwehand W, Daumer M. Schimpl M, et al. PLoS One. 2011;6(8):e23299. doi: 10.1371/journal.pone.0023299. Epub 2011 Aug 10. PLoS One. 2011. PMID: 21853107 Free PMC article.
Participants were a median (interquartile range[IQR]) age of 49 (16) years; 45% women; and had a median (IQR) BMI of 26 (5.4). ...This was subsequently validated in a separate 'closed' dataset that showed a decrease of walking speed of -0.0037 m/s per …
Participants were a median (interquartile range[IQR]) age of 49 (16) years; 45% women; and had a median (IQR) BMI of 26 (5.4). …
111 results
Jump to page
Feedback